Junmin Song
Clinical FellowAbout
Research
Publications
Featured Publications
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial
Park W, O’Connor CA, Chou JF, Hilmi M, Tarcan Z, Schwartz C, Larsen M, Homsi R, Sivaprakasam K, Umeda S, Perry MA, Varghese AM, Yu KH, Balogun F, Zervoudakis A, Katz SS, Kim TH, Zhao K, Richards AL, Lecomte N, Martin Muldoon D, Karnoub E, Chatila W, Yang J, El-Dika I, Rao D, Joshi S, Foote MB, Sugarman R, Harding JJ, Epstein AS, Kelsen D, Chalassani S, Keane F, Schoenfeld JD, Singhal A, Diguglielmo E, Bandlamudi C, Song J, Ozkan HS, Hong J, Zhang H, Cardenas AI, Lao M, Melchor J, Shah R, Kang W, Mazzoni F, Soares K, Donoghue MT, Santos E, Rolston V, Reyngold M, Wei ACC, Tipping M, Basturk O, Berger M, Kihn Do R, Schattner M, Jarnagin WR, Riaz N, Balachandran V, Pe’er D, Capanu M, Iacobuzio-Donahue C, O’Reilly EM. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Nature Medicine 2026, 32 DOI: 10.1038/s41591-026-04299-5.Peer-Reviewed Original ResearchTreatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC
Lee M, Song J, Miao E, Alicea DS, Zhang C, Xue X, Tuckman S, Yang J, D’Aiello A, Gucalp R, Stiles B, Ohri N, Halmos B, Cheng H. Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC. Npj Precision Oncology 2026, 10: 90. DOI: 10.1038/s41698-025-01259-z.Peer-Reviewed Original ResearchUpdate 2025: Management of Non‑Small-Cell Lung Cancer
Jeon H, Wang S, Song J, Gill H, Cheng H. Update 2025: Management of Non‑Small-Cell Lung Cancer. Lung 2025, 203: 53. DOI: 10.1007/s00408-025-00801-x.Peer-Reviewed Original ResearchThoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approaches
Song J, Gersten A, Herzberg B, Halmos B. Thoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approaches. The Oncologist 2025, 30: oyaf121. PMID: 40421964, PMCID: PMC12107547, DOI: 10.1093/oncolo/oyaf121.Peer-Reviewed Original ResearchConceptsSMARCA4-UTThoracic SMARCA4-deficient undifferentiated tumorSMARCA4-deficient undifferentiated tumorAggressive clinical behaviorTargeted clinical trialsThoracic tumorsUndifferentiated tumorsHistological presentationClinical behaviorPoor prognosisDifferential diagnosisImmunohistochemical evaluationEffective therapyDiagnostic pathwayClinical trialsDisease entityMolecular basisMolecular evaluationTumorThoracicDiagnosisTreatment implicationsDiagnostic complexPrognosisTherapyTeclistamab versus B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis
Song J, Chiang C, Esagian S, Kim G, Chi K, Chang Y, Parker T, Mehta A. Teclistamab versus B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis. Haematologica 2025, 110: 2498-2502. PMID: 40207713, PMCID: PMC12485301, DOI: 10.3324/haematol.2024.287215.Peer-Reviewed Original ResearchGlucagon-like Peptide‐1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors
Chiang C, Song J, Chi K, Chang Y, Xanthavanij N, Chang Y, Hsia Y, Chiang C, Ghamari A, Reynolds K, Lin S, Xu X, Neilan T. Glucagon-like Peptide‐1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors. European Journal Of Cancer 2024, 216: 115170. PMID: 39709670, DOI: 10.1016/j.ejca.2024.115170.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1 agonistsImmune checkpoint inhibitorsImmune-related adverse eventsSerious adverse eventsAdverse eventsAll-Cause MortalityCardiovascular eventsCheckpoint inhibitorsEfficacy outcomesCoronary revascularizationHeart failureOccurrence of immune-related adverse eventsCancer patientsLower risk of MACEMedian 12-month follow-upLow riskMyocardial infarctionComposite of myocardial infarctionRisk of adverse eventsRisk of MACEType 2 diabetes mellitusReduce cardiovascular eventsIndividual components of MACEComponents of MACEPeptide-1 agonists
2026
Sequencing strategy of immunotherapy with chemoradiotherapy in stage III non–small cell lung cancer: A pooled analysis of prospective trials.
Li Y, Song J, Song X, Zhang X, Stefani H, Ezhilarasu P, Li F, Ohri N, Cheng H. Sequencing strategy of immunotherapy with chemoradiotherapy in stage III non–small cell lung cancer: A pooled analysis of prospective trials. Journal Of Clinical Oncology 2026, 44: e20041-e20041. DOI: 10.1200/jco.2026.44.16_suppl.e20041.Peer-Reviewed Original ResearchGLP-1 Receptor Agonist Use and Survival Among Patients With Type 2 Diabetes and Brain Metastases
Chi K, Chang Y, Song J, Chen C, Perng P, Lin H. GLP-1 Receptor Agonist Use and Survival Among Patients With Type 2 Diabetes and Brain Metastases. JAMA Network Open 2026, 9: e261311. PMID: 41811319, PMCID: PMC12980253, DOI: 10.1001/jamanetworkopen.2026.1311.Peer-Reviewed Original Research
2025
Comparison of anticoagulants and risk of ischemic stroke in patients with acute cancer-associated venous thromboembolism
Ma S, Chang Y, Chiang C, Song J, Lee Y, Chang K, Redd R, Chiasakul T, McCarthy E, Zwicker J, Patell R, Leader A. Comparison of anticoagulants and risk of ischemic stroke in patients with acute cancer-associated venous thromboembolism. Blood Advances 2025, 10: 14-24. PMID: 40845270, PMCID: PMC12803923, DOI: 10.1182/bloodadvances.2025017523.Peer-Reviewed Original ResearchRisk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.
Ko A, Chang Y, Bahar F, Wang T, Xanthavanij N, Yu C, Hsieh R, See X, Lo S, Song J, Hsia Y, Chiang C, Xu X, Lin S, Chiang C. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis. Annals Of Internal Medicine 2025, 179: 216-229. PMID: 41359966, DOI: 10.7326/annals-25-02237.Peer-Reviewed Original ResearchConceptsRisk of biasGlucagon-like peptide-1 receptor agonistsCochrane Central RegisterCancer outcomesCochrane riskPeptide-1 receptor agonistsOdds ratioCochrane Risk of Bias 2 toolGLP-1RARisk of Bias 2 toolObesity-related cancersRandom-effects meta-analysisMeta-analysisLow risk of biasCertainty of evidenceLow riskReceptor agonistsCochrane Central Register of Controlled TrialsCentral Register of Controlled TrialsMultiple myelomaKidney cancerRegister of Controlled TrialsWeb of ScienceSensitivity analysis of trialsRandomized placebo-controlled trial
Academic Achievements & Community Involvement
Get In Touch
Contacts
Email